The HIF pathway in cancer

被引：156

作者：

Maxwell, PH ^{[1
]}

机构：

[1] Univ London Imperial Coll Sci Technol & Med, Renal Sect, London W12 0NN, England

来源：

SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY | 2005年 / 16卷 / 4-5期

基金：

英国惠康基金;

关键词：

HIF; VHL; hypoxia; cancer; angiogenesis;

D O I：

10.1016/j.semcdb.2005.03.001

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

The transcription factor hypoxia-inducible factor-1 (HIF) is commonly activated in cancer. This has major effects on gene expression, and is important in tumor angiogenesis. Besides being activated by low oxygen, genetic events in cancer contribute to activating HIF. Most striking is that loss of function of the VHL tumour suppressor protein results in constitutive activation of the HIF pathway. An important aim is to define the contribution of HIF activation to the evolution of different cancers, and its potential as a therapeutic target. (c) 2005 Elsevier Ltd. All rights reserved.

引用

页码：523 / 530

页数：8

共 66 条

[31] Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway [J].

Kung, AL ;

Zabludoff, SD ;

France, DS ;

Freedman, SJ ;

Tanner, EA ;

Vieira, A ;

Cornell-Kennon, S ;

Lee, J ;

Wang, BQ ;

Wang, JM ;

Memmert, K ;

Naegeli, HU ;

Petersen, F ;

Eck, MJ ;

Bair, KW ;

Wood, AW ;

Livingston, DM .

CANCER CELL, 2004, 6 (01) :33-43

[32] Asparagine hydroxylation of the HIF transactivation domain: A hypoxic switch [J].

Lando, D ;

Peet, DJ ;

Whelan, DA ;

Gorman, JJ ;

Whitelaw, ML .

SCIENCE, 2002, 295 (5556) :858-861

[33] Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth [J].

Mack, FA ;

Rathmell, WK ;

Arsham, AM ;

Gnarra, J ;

Keith, B ;

Simon, MC .

CANCER CELL, 2003, 3 (01) :75-88

[34]

Madden SL, 1996, CANCER RES, V56, P5384

[35] mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways [J].

Majumder, PK ;

Febbo, PG ;

Bikoff, R ;

Berger, R ;

Xue, Q ;

McMahon, LM ;

Manola, J ;

Brugarolas, J ;

McDonnell, TJ ;

Golub, TR ;

Loda, M ;

Lane, HA ;

Sellers, WR .

NATURE MEDICINE, 2004, 10 (06) :594-601

[36] Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression [J].

Makino, Y ;

Cao, RH ;

Svensson, K ;

Bertilsson, GR ;

Åsman, M ;

Tanaka, H ;

Cao, YH ;

Berkenstam, A ;

Poellinger, L .

NATURE, 2001, 414 (6863) :550-554

[37] HIF activation identifies early lesions in VHL kidneys: Evidence for site-specific tumor suppressor function in the nephron [J].

Mandriota, SJ ;

Turner, KJ ;

Davies, DR ;

Murray, PG ;

Morgan, NV ;

Sowter, HM ;

Wykoff, CC ;

Maher, ER ;

Harris, AL ;

Ratcliffe, PJ ;

Maxwell, PH .

CANCER CELL, 2002, 1 (05) :459-468

[38] The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis [J].

Maxwell, PH ;

Wiesener, MS ;

Chang, GW ;

Clifford, SC ;

Vaux, EC ;

Cockman, ME ;

Wykoff, CC ;

Pugh, CW ;

Maher, ER ;

Ratcliffe, PJ .

NATURE, 1999, 399 (6733) :271-275

[39] Multiple splice variants of the human HIF-3α locus are targets of the von Hippel-Lindau E3 uhiquitin ligase complex [J].

Maynard, MA ;

Qi, H ;

Chung, J ;

Lee, EHL ;

Kondo, Y ;

Hara, S ;

Conaway, RC ;

Conaway, JW ;

Ohh, M .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (13) :11032-11040

[40] HLF/HIF-2α is a key factor in retinopathy of prematurity in association with erythropoietin [J].

Morita, M ;

Ohneda, O ;

Yamashita, T ;

Takahashi, S ;

Suzuki, N ;

Nakajima, O ;

Kawauchi, S ;

Ema, M ;

Shibahara, S ;

Udono, T ;

Tomita, K ;

Tamai, M ;

Sogawa, K ;

Yamamoto, M ;

Fujii-Kuriyama, Y .

EMBO JOURNAL, 2003, 22 (05) :1134-1146

← 1 2 3 4 5 6 7 →